Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Hidden GMP Failure Detected in Inspection — Drug Approval Halted

A planned expansion of Regeneron’s flagship Eylea HD product has been rejected by the US FDA after a key fill-finish manufacturing site failed to meet GMP inspection standards, triggering a full regulatory setback and delaying a major lifecycle upgrade.
  • News
Hidden GMP Failure Detected in Inspection — Drug Approval Halted

Pharmaceutical Audits in 2026: GMP Audit Checklist and Findings

Explore how pharmaceutical internal audits and GMP audit checklist practices enhance inspection readiness, strengthen pharmaceutical quality system compliance, and reduce recurring audit findings. Learn how data integrity controls and structured audit processes support effective regulatory audit performance.
  • Blog, Quality Management System
GMP internal audit pharma process showing pharmaceutical audit checklist GMP execution, data integrity audit trail pharma verification, and inspection readiness assessment within a pharmaceutical quality system.

Novo Nordisk Faces FDA Warning Letter — Missed Death Reports Expose Pharmacovigilance Failure

FDA issues warning letter to Novo Nordisk over missing safety reports and death data gaps in pharmacovigilance systems, citing serious compliance breakdowns and increasing inspection risk.
  • News
Pharmacovigilance specialist analyzing drug safety data and regulatory reports in a digital pharmaceutical monitoring system with AI-driven risk visualization dashboards.

CMC vs GMP in 2026: Key Differences and Inspection Findings

This article explains the regulatory relationship between CMC and GMP, highlighting key differences, inspection findings, and compliance expectations. It shows how documentation, validation, and manufacturing control connect to FDA and global pharmaceutical quality system requirements.
  • Blog, Validation and Qualification
CMC vs GMP difference in pharmaceutical quality system showing regulatory compliance, process validation, data integrity, and manufacturing control aligned with FDA and ICH Q10 expectations in a GMP inspection environment.

IQ OQ PQ in 2026: Equipment Qualification Protocol Guide

This article explains how equipment qualification supports GMP compliance through structured validation stages. It highlights common inspection findings, documentation requirements, and risk-based validation lifecycle approach to help reduce validation deviation trends pharma inspections and improve audit readiness.
  • Blog, Validation and Qualification
Infographic showing equipment qualification stages in pharmaceutical validation including installation, operational, and performance testing aligned with GMP validation requirements IQ OQ PQ guide and data integrity in qualification documentation.

GMP regulations in 2026: FDA EU Inspection Checklist Guide

This article provides a practical overview of GMP regulations in 2026, covering FDA 21 CFR 210/211, EU GMP guidelines EudraLex Volume 4, and WHO expectations. It explains inspection trends, audit readiness, and regulatory compliance gaps in pharmaceutical manufacturing systems.
  • Blog, Quality Management System
GMP regulations checklist pharma visual illustrating EU GMP guidelines EudraLex Volume 4, FDA 21 CFR 210 211 compliance guide, and data integrity requirements GMP inspections in pharmaceutical manufacturing environment.

PICS Guide in 2026: GMP Inspection Checklist and Compliance

This article explains how GMP inspections are structured using the PICS guideline, focusing on checklist execution, data integrity controls, and system-level compliance gaps. It highlights real inspection expectations and how companies can improve audit readiness effectively.
  • Blog, Quality Management System
GMP inspection checklist PICS based visual showing inspection expectations, data integrity review, and quality system gaps aligned with pharmaceutical inspection cooperation scheme standards and compliance evaluation process.

EU Annex 11 in 2026 GMP Inspection Requirements for Data Integrity and Computerized Systems

This article explores computerized system compliance in pharmaceutical environments, focusing on validation lifecycle, audit trail integrity, and risk-based approaches. It highlights regulatory expectations for electronic records, system controls, and inspection readiness under EU GMP frameworks and GxP standards.
  • Blog, Computerized System Validation, GMP
Pharmaceutical data integrity ALCOA plus EU GMP with system access control and audit trail compliance requirements in regulated systems.

Annex 1 in 2026 GMP Inspection Requirements for Sterile Manufacturing

This article explains how EU GMP Annex 1 defines sterile manufacturing requirements, focusing on contamination control strategy, cleanroom classification, and aseptic processing. It highlights GMP inspection findings and shows how facilities can improve compliance and inspection readiness effectively.
  • Blog, Validation and Qualification
EU GMP Annex 1 sterile manufacturing environment displaying cleanroom classification ISO 14644 compliance, aseptic processing operations, environmental monitoring systems, and GMP inspection-focused contamination control strategy CCS implementation.

GAMP 5 in 2026: Trends and Compliance Insights

This article explains computerized system validation in regulated environments, focusing on CSV life cycle controls, data integrity compliance, and risk-based validation principles. It also highlights inspection expectations, supplier assessment guidance, and audit trail requirements under FDA Part 11 and EU
  • Blog, Validation and Qualification
Computerized system validation workflow showing validation lifecycle model, supplier assessment guidance, and audit trail requirements aligned with FDA Part 11 electronic records and EU Annex 11 requirements.